Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Clinical breakpoints (CBPs) and epidemiological cutoff values (ECVs) have been established for several Candida spp. and the newer triazoles and echinocandins but are not yet available for older antifungal agents, such as amphotericin B, flucytosine, or itraconazole. We determined species-specific ECVs for amphotericin B (AMB), flucytosine (FC) and itraconazole (ITR) for eight Candida spp. (30,221 strains) using isolates from 16 different laboratories in Brazil, Canada, Europe, and the United States, all tested by the CLSI reference microdilution method. The calculated 24- and 48-h ECVs expressed in μg/ml (and the percentages of isolates that had MICs less than or equal to the ECV) for AMB, FC, and ITR, respectively, were 2 (99.8)/2 (99.2), 0.5 (94.2)/1 (91.4), and 0.12 (95.0)/0.12 (92.9) for C. albicans ; 2 (99.6)/2 (98.7), 0.5 (98.0)/0.5 (97.5), and 2 (95.2)/4 (93.5) for C. glabrata ; 2 (99.7)/2 (97.3), 0.5 (98.7)/0.5 (97.8), and 05. (99.7)/0.5 (98.5) for C. parapsilosis ; 2 (99.8)/2 (99.2), 0.5 (93.0)/1 (90.5), and 0.5 (97.8)/0.5 (93.9) for C. tropicalis ; 2 (99.3)/4 (100.0), 32 (99.4)/32 (99.3), and 1 (99.0)/2 (100.0) for C. krusei ; 2 (100.0)/4 (100.0), 0.5 (95.3)/1 (92.9), and 0.5 (95.8)/0.5 (98.1) for C. lusitaniae ; −/2 (100.0), 0.5 (98.8)/0.5 (97.7), and 0.25 (97.6)/0.25 (96.9) for C. dubliniensis ; and 2 (100.0)/2 (100.0), 1 (92.7)/−, and 1 (100.0)/2 (100.0) for C. guilliermondii . In the absence of species-specific CBP values, these wild-type (WT) MIC distributions and ECVs will be useful for monitoring the emergence of reduced susceptibility to these well-established antifungal agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a recent study of 9,252 clinical isolates of C. albicans, 99.8% remained AmB-sensitive [11].”
From Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B (2013) · cites this paper as [11]
In the citing paper
“After 50 years of use as monotherapy, the acquisition of AmB resistance in C. albicans remains extremely rare.”
From Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B (2013) · cites this paper as [11]
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [46]
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“Whereas the use of the newer triazoles and echinocandins for the treatment of invasive candidiasis (IC) continues to increase (20), the older, established agents, amphotericin B (both conventional and lipid formulations), flucytosine, and itraconazole, also serve as additional systemically active agents for empirical,…”
BackgroundSelf-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706 · cited 1×
“Whereas the use of the newer triazoles and echinocandins for the treatment of invasive candidiasis (IC) continues to increase (20), the older, established agents, amphotericin B (both conventional and lipid formulations), flucytosine, and itraconazole, also serve as additional systemically active agents for empirical,…”
BackgroundComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · cited 1×
“Whereas MIC data from clinical trials (18, 33, 35, 37) and population-based surveillance (22) show a restricted range of 0.”
MethodRex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 2×
“Whereas MIC data from clinical trials (18, 33, 35, 37) and population-based surveillance (22) show a restricted range of 0.”
BackgroundMethodSelf-citationRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 13×
“The finding that the majority of Candida sp. isolates have an MIC for flucytosine of 0.5 g/ml raises concern that the CLSI CBPs of 4 g/ml (susceptible), 8 to 16 g/ml (intermediate), and 32 g/ml (resistant) are entirely too high and are likely to be insensitive to the development of decreased susceptibility to flucytos…”
MethodInfluentialSelf-citationParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge, J., & Paterson, D. L. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-06 · Cited by 578
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498 · cited 1×
“Although abundant MIC data are available for each of these older antifungal agents (7, 15, 19, 22, 27, 31, 35, 37), CBPs are either flawed (flucytosine and itraconazole) or nonexistent (amphotericin B), and ECVs have not been described for these agents and any Candida species.”
BackgroundSelf-citationKao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457 · cited 1×
“These data are consistent with those reported previously (2, 6, 11, 14, 31) and document the excellent potency and spectrum of flucytosine against most Candida spp.”
ResultSelf-citationAntifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · cited 18×
“The finding that the majority of Candida sp. isolates have an MIC for flucytosine of 0.5 g/ml raises concern that the CLSI CBPs of 4 g/ml (susceptible), 8 to 16 g/ml (intermediate), and 32 g/ml (resistant) are entirely too high and are likely to be insensitive to the development of decreased susceptibility to flucytos…”
BackgroundMethodInfluentialSelf-citationComparison of Methods: Different Methods of Converting Vibrations to Electricity
Roundy, S., Wright, P. K., & Rabaey, J. M. (2004) · Energy Scavenging for Wireless Sensor Networks · doi:10.1007/978-1-4615-0485-6_3 · Cited by 422
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397 · cited 1×
“The typical MIC distribution for WT organisms covers three to five doubling dilutions surrounding the modal MIC (1, 13, 38).”
BackgroundEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397 · cited 2×
“The typical MIC distribution for WT organisms covers three to five doubling dilutions surrounding the modal MIC (1, 13, 38).”
BackgroundHas antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 2×
“, suggesting that treatment with this agent alone may not be optimal (34, 37).”
BackgroundSelf-citationPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334 · cited 3×
“Organisms with acquired or mutational resistance mechanisms may be included among those for which the MIC results are higher than the ECV (1, 13, 30).”
BackgroundSelf-citationPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · cited 2×
“Furthermore, this may be considered a necessary step toward the development, or revision, of useful, species-specific CBPs (23, 24, 29, 30).”
BackgroundSelf-citationRex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Self-citationMolecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
Self-citationDodgson, A. R., Dodgson, K. J., Pujol, C., Pfaller, M. A., & Soll, D. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2223-2227.2004 · Cited by 133
Self-citationPfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3518-3521.2002 · Cited by 132 · cited 2×
“Although abundant MIC data are available for each of these older antifungal agents (7, 15, 19, 22, 27, 31, 35, 37), CBPs are either flawed (flucytosine and itraconazole) or nonexistent (amphotericin B), and ECVs have not been described for these agents and any Candida species.”
BackgroundResultSelf-citationPfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130 · cited 2×
“Furthermore, this may be considered a necessary step toward the development, or revision, of useful, species-specific CBPs (23, 24, 29, 30).”
BackgroundSelf-citationDiekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125 · cited 1×
“Although abundant MIC data are available for each of these older antifungal agents (7, 15, 19, 22, 27, 31, 35, 37), CBPs are either flawed (flucytosine and itraconazole) or nonexistent (amphotericin B), and ECVs have not been described for these agents and any Candida species.”
BackgroundSelf-citationPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 5×
“Analyses of both clinical trial data (35) and clinical and microbiological data from population-based surveillance (22) have failed to establish any clinical correlation between amphotericin B MICs and clinical outcome.”
BackgroundMethodInfluentialVancomycin use--an historical review
Griffith, R. S. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.1 · Cited by 91
Mutational Analysis of Flucytosine Resistance in Candida glabrata
Edlind, T. D., & Katiyar, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00605-10 · Cited by 83 · cited 2×
“In the related species C. dubliniensis, McManus et al. (17) found that isolates with a homozygous mutation in FCY1 (which encodes the deaminase) demonstrated high-level resistance (MIC, 128 g/ml) and those without a mutation all had flucytosine MICs of 0.25 g/ ml. Edlind and Katiyar (9) demonstrated that the haploid y…”
BackgroundInfluentialPfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.3807-3810.2005 · Cited by 82 · cited 2×
“Although abundant MIC data are available for each of these older antifungal agents (7, 15, 19, 22, 27, 31, 35, 37), CBPs are either flawed (flucytosine and itraconazole) or nonexistent (amphotericin B), and ECVs have not been described for these agents and any Candida species.”
BackgroundSelf-citationFlucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans
Pujol, C., Pfaller, M. A., & Soll, D. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.262-266.2004 · Cited by 80
Self-citationFlucytosine Primary Resistance in Candida Species and Cryptococcus neoformans
Cuenca‐Estrella, M., Díaz-Guerra, T. M., Mellado, E., & Rodríguez-Tudela, J. L. (2001) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00011265 · Cited by 70 · cited 1×
“These data are consistent with those reported previously (2, 6, 11, 14, 31) and document the excellent potency and spectrum of flucytosine against most Candida spp.”
ResultSelf-citationHoban, D. J., Zhanel, G. G., & Karlowsky, J. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1463 · Cited by 64 · cited 1×
“These data are consistent with those reported previously (2, 6, 11, 14, 31) and document the excellent potency and spectrum of flucytosine against most Candida spp.”
ResultArendrup, M. C., Kahlmeter, G., Rodriguez-Tudela, J. L., & Donnelly, J. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-08 · Cited by 62 · cited 2×
“The typical MIC distribution for WT organisms covers three to five doubling dilutions surrounding the modal MIC (1, 13, 38).”
BackgroundPfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., & Jones, R. N. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05047-11 · Cited by 62
Self-citationPfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61 · cited 1×
“(25) established epidemiological cutoff values (ECVs) to differentiate wildtype (WT) strains (those without mutational or acquired resistance mechanisms) from non-WT strains (those having mutational or acquired resistance mechanisms) as a means of tracking the emergence of reduced susceptibility to posaconazole among…”
BackgroundSelf-citationMolecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata
Vandeputte, P., Pineau, L., Larcher, G., Noel, T., Brèthes, D., Chabasse, D., & Bouchara, J.-P. (2011) · Mycopathologia · doi:10.1007/s11046-010-9342-1 · Cited by 55
Primary resistance to flucytosine among clinical isolates of Candida spp.
Barchiesi, F., Arzeni, D., Caselli, F., & Scalise, G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.3.408 · Cited by 53 · cited 1×
“These data are consistent with those reported previously (2, 6, 11, 14, 31) and document the excellent potency and spectrum of flucytosine against most Candida spp.”
ResultFlorent, M., Noël, T., Ruprich-Robert, G., Da Silva, B., Fitton-Ouhabi, V., Chastin, C., Papon, N., & Chapeland-Leclerc, F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00880-08 · Cited by 52 · cited 1×
“lusitaniae (10), various patterns of reduced susceptibility to flucytosine have been elucidated, depending on the mutations present.”
BackgroundEbert, R. H., & Brown, S. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198305193082006 · Cited by 50
Amphotericin B resistance testing of Candida spp.: a comparison of methods
Law, D. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.109 · Cited by 44 · cited 1×
“Although abundant MIC data are available for each of these older antifungal agents (7, 15, 19, 22, 27, 31, 35, 37), CBPs are either flawed (flucytosine and itraconazole) or nonexistent (amphotericin B), and ECVs have not been described for these agents and any Candida species.”
BackgroundMartinez-Suarez, J. V., & Rodriguez-Tudela, J. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1512 · Cited by 34
Laboratory methods for flucytosine (5-fluorocytosine)
Speller, D. C. E., Cartwright, R. Y., Evans, E. G. V., Hay, R. J., Mackenzie, D. W. R., Milne, L. J. R., Odds, F. C., Warnock, D. W., & Wingfield, H. J. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.1.1 · Cited by 33
McManus, B. A., Moran, G. P., Higgins, J. A., Sullivan, D. J., & Coleman, D. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00607-09 · Cited by 24 · cited 1×
“(17) found that isolates with a homozygous mutation in FCY1 (which encodes the deaminase) demonstrated high-level resistance (MIC, 128 g/ml) and those without a mutation all had flucytosine MICs of 0.”
BackgroundAntifungal use in hospitalized adults in U.S. academic health centers
Pakyz, A. L., Gurgle, H. E., & Oinonen, M. J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100423 · Cited by 22 · cited 1×
“Whereas the use of the newer triazoles and echinocandins for the treatment of invasive candidiasis (IC) continues to increase (20), the older, established agents, amphotericin B (both conventional and lipid formulations), flucytosine, and itraconazole, also serve as additional systemically active agents for empirical,…”
BackgroundPfaller, M. A., & Diekema, D. J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0022-x · Cited by 16
Self-citation
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
“Breakpoints have been established for most, but not all, drugs for the 5 most common Candida species [47, 50, 121, 122] (Table 1).”
BackgroundSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
“In recent years, studies by the CLSI Subcommittee on Antifungal Susceptibility Testing and collaborating investigators have generated data to support a more rapid time for MIC result reporting (39, 61, 71, 72), established epidemiological cutoff values (ECVs) for Candida and the systemically active antifungal agents (…”
BackgroundMethodSelf-citationCandida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“8% remained AmBsensitive [11].”
Metadata
- Authors
- Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., Lockhart, S. R., Martin-Mazuelos, E., Melhem, M. S. C., Ostrosky-Zeichner, L., Pappas, P., Pelaez, T., Peman, J., Rex, J., & Szeszs, M. W.
- Affiliations
- JMI Laboratories (US)
- Virginia Commonwealth University Medical Center (US)
- Unidad de Microbiologia Experimental, Hospital Universitario La Fe, Valencia, Spain
- Servicio de Micologia, Centro National de Microbiologia, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo, Spain
- University of Iowa (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alberta (CA)
- University Hospitals of Cleveland (US)
- Centers for Disease Control and Prevention (US)
- Hospital Universitario de Valme, Seville, Spain
- The Adolfo Lutz Institute Public Health Reference Center, Rio Claro, Brazil
- University of Texas Health Science Center, Houston, Texas, USA
- University of Alabama at Birmingham (US)
- Hospital General Universitario Gregorio Marañon, Facultad de Medicina, Universidad Complutense, Madrid, Spain
- Servicio de Microbiologia, Hospital Universitario La Fe, Valencia, Spain
- AstraZeneca (United Kingdom) (GB)
- Instituto Adolfo Lutz (BR)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2012-06
- Volume
- 50
- Issue
- 6
- Pages
- 2040-2046
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC3372147
- OpenAlex
- W2141374001
- Cited by
- 174
- References
- 45
- Citations by year
- 2026: 15 · 2025: 8 · 2024: 11 · 2023: 19 · 2022: 8 · 2021: 16 · 2020: 6 · 2019: 11 · 2018: 9 · 2017: 10 · 2016: 11 · 2015: 16 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- epidemiological cut-off values, Candida, amphotericin B, 5-fluorocytosine, itraconazole, minimum inhibitory concentration, clinical breakpoints, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida dubliniensis, antifungal susceptibility
- MeSH terms
- Amphotericin B, Antifungal Agents, Brazil, Canada, Candida, Candidiasis, Europe, Flucytosine, Humans, Microbial Sensitivity Tests, United States, Itraconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.